Stock

Protagonist Therapeutics, Inc. PTGX

$135.97+0.45%

All stocks Create account to unlock

Overview

PTGX market data

Price History

PTGX price chart

Valuation & Profitability

no valuation data

No Valuation Data Yet

Alpha Vantage and Twelve Data both returned no valuation metrics for PTGX. Check back after the next daily valuation refresh — this symbol may be new, delisted, or temporarily unavailable from both providers.

Company news

7 captured

Barclays Maintains Overweight on Protagonist Therapeutics, Raises Price Target to $151 · Jul 14, 2026, 11:39 AM

Truist Securities Maintains Buy on Protagonist Therapeutics, Raises Price Target to $145 · Jul 7, 2026, 11:45 AM

This $300 Million Biotech May Be Deeply Mispriced: Analyst · Jun 24, 2026, 6:25 PM

AbbVie Expands Immunology Footprint With Apogee $11 Billion Acquisition · Jun 22, 2026, 1:20 PM

8-K filing — Protagonist Therapeutics, Inc (PTGX) · Jun 18, 2026, 8:30 PM

Silence Therapeutics Stock Rises On Positive Blood Cancer Drug Data · Jun 12, 2026, 2:50 PM

Protagonist Therapeutics To Present Four Abstracts On Rusfertide In Polycythemia Vera At 2026 European Hematology Association Congress In Sweden · Jun 1, 2026, 11:20 AM

Decision & Score

Members

Our Tradable / Watch / Avoid decision and 0–100 conviction score for this symbol are members-only.

Create account to unlock

Trend & Pattern Evidence

Members

Trend alignment and backtested chart-pattern probabilities are members-only.

Create account to unlock

Sector Peer Ranking

Members

Ranked sector peers with scores and decisions are members-only.

Create account to unlock